St. Paul, MN – VivaQuant has been awarded a Phase II Small Business Innovation Research (SBIR) grant from the National Institute on Drug Abuse of the National Institutes of Health (NIH) to complete development of a small wearable device targeted at providing more accurate and timely information to physicians caring for patients with atrial fibrillation and other arrhythmias. The device will employ VivaQuant’s proprietary MultiDomain Signal Processing (MDSPTM) technology to improve arrhythmia detection accuracy and ECG readability. The advanced signal processing capabilities and other features of the device are expected to substantially reduce the cost of evaluating arrhythmia burden and provide a more comfortable experience for the 4 million patients that undergo at home arrhythmia testing each year in the U.S. With commercialization of its MDSP technology, VivaQuant will address a significant unmet need in the $23.3bn global cardiac monitoring market.

NIH awards SBIR grants to fund research and development of groundbreaking technologies with significant commercial potential and benefit to society. “The review process for SBIR grants is highly competitive. Receiving this award speaks volumes about the potential for our technology,” says VivaQuant CTO Dr. Marina Brockway.

“This Phase II grant was awarded following successful demonstration in a Phase I SBIR grant that it was feasible to implement our MDSP ECG processing technology in a tiny computer chip and process ECGs with very high accuracy and ultra-low power. This provides a nice credibility boost and will greatly accelerate commercialization of our technology for patient care.”

This work is being funded by NIDA under grant award # R44DA041815.

About VivaQuant

VivaQuant provides hardware, software and embedded algorithms for processing ECGs as well as ECG data analysis services. Its Multi-Domain Signal Processing (MDSPTM) technology has been shown to remove 95% of noise from ambulatory ECGs while preserving fidelity, significantly reduce analysis and reporting labor, and greatly improve the accuracy of information extracted for diagnostic and cardiac safety purposes. The AE-1010 software has not been approved by the FDA or any other regulatory body for use in diagnosing or treating a disease.

For additional information visit, call (651) 383-2315, or email [email protected].

Read this press release on